Will a new type of immunotherapy help prevent tumors from developing resistance to chemotherapy? Research is underway.
Researchers are testing a new drug for second-line therapy (after initial treatment stops working) in metastatic pancreatic cancer.
Dr. Tanios Bekaii-Saab explains the early positive results from the NAPOLI-3 clinical trial, testing the NALIRIFOX combination.
Researchers are testing a drug that penetrates the stroma, to make radiotherapy work better for advanced pancreatic cancer patients.
A new clinical trial looks at a special diet that tries to curb a patient’s metabolism to slow cancer growth during chemotherapy.
A clinical trial is testing a drug combination including a drug used for erectile dysfunction, a new drug, and two immunotherapy drugs.
Dr. Wungki Park leads a trial that uses a monoclonal antibody to target a protein that is common in pancreatic cancer.
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Dr. Tanios Bekaii-Saab reports on the disappointing results of a trial combining an angiogenesis inhibitor and mFOLFIRINOX.